- Case report
- Open Access
Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report
Journal of Medical Case Reports volume 10, Article number: 298 (2016)
Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures.
We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance.
The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment.
Multifocal choroiditis (MFC) with panuveitis is a rare, recurrent white dot syndrome affecting myopic women in their third to fourth decades. Symptoms include blurred vision, photopsia, or scotoma . Clinical findings comprise vitritis and multiple, small, round, yellowish lesions at the level of the retinal pigment epithelium and choriocapillaris at the posterior pole and in the periphery. The presence of anterior uveitis or vitritis seems to have prognostic implications . Characteristically the lesions are hypofluorescent in fluorescein angiography (FA) and indocyanine green angiography (ICGA) . During the course of the disease the lesions become hyperpigmented . Treatment encompasses systemic or periocular steroids and immunosuppression. Secondary choroidal neovascularization (CNV) occurs in 27 to 46 % of cases [1, 3–6]. It can be treated by intravitreal anti-vascular endothelial growth factor (VEGF) application, laser photocoagulation, photodynamic therapy, or surgical excision [3, 4].
We present a 3-year course of a young myopic white woman with MFC and secondary CNV. The activity of the disease was evaluated clinically by optical coherence tomography (OCT; Stratus, Carl-Zeiss-Meditec, Inc.) and FA. Intravitreal bevacizumab (2.5 mg/0.1 ml) was injected after informed consent was given. Retreatment depended on visual acuity (VA), OCT, and FA findings. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures. In addition, it displays why diagnosis can be difficult in the beginning and emphasizes the therapeutic importance of systemic immunosuppression.
A 22-year-old white woman presented with decreased VA and a central floater in her right eye (OD) for 2 weeks. Apart from bilateral high myopia of –14 diopter ophthalmological, her general and family history were unremarkable. Her Snellen VA was 20/32 in her OD and 20/20 in her left eye (OS). Her intraocular pressure was normotonic. Funduscopy revealed a myopic fundus with lacquer crack and small macular hemorrhage in her OD (Fig. 1a). OCT showed discrete subretinal fluid suspicious for CNV. FA was consistent with CNV (Fig. 2a). She did not show up for further examinations for personal reasons.
She presented again 11 months later with a loss of VA and floaters in her OD. In the meantime she had received intravitreal bevacizumab (2.5 mg/0.1 ml) for CNV in her OS elsewhere. Her VA was 20/200 in her OD and 20/32 in her OS. A clinical examination showed vitreous cells and roundish yellow to gray chorioretinal lesions in the central and midperipheral fundus bilaterally. A small subretinal hemorrhage (Fig. 1b) was found in her OD and macular fibrosis was found in her OS. In FA the multiple lesions were hypofluorescent in early phase and hyperfluorescent in late phase. A discrete macular leakage corresponded to a subfoveal CNV in her OD (Fig. 2b). Borreliosis, toxoplasmosis, and syphilis were ruled out serologically. A clinical examination did not show any evidence of tuberculosis or sarcoidosis and MFC with panuveitis was diagnosed. A combined treatment of oral steroids (prednisolone 60 mg daily administered orally, tapered off gradually) and intravitreal bevacizumab in her OD was started. Subsequently, cyclosporine was administered orally. One month later VA in her OS dropped to 20/100 with a corresponding late leakage in FA which was compatible with CNV reactivation. Bevacizumab was re-injected in her OS.
During the following 15 months the number of inflammatory lesions remained constant with ongoing pigmentation (Fig. 1c) indicating absent active inflammation. Her VA increased to 20/100 in her OD and 20/25 in her OS. Systemic immunosuppression was discontinued. However, 1 month and 7 months later CNV recurred in her OS. Bevacizumab was re-injected twice. Three years after her first presentation her VA was 20/40 in her OD and 20/200 in her OS.
The case reported is of educational merit because of its impressive ocular fundus pictures. In addition, it is remarkable in terms of diagnostics because of the delayed onset of peripheral lesions and the additional existence of high myopia that made diagnosis of MFC difficult. CNV in MFC occurs in 27 to 46 % of cases [1, 3–6] and can be the first symptom . MFC lesions may be clinically occult, which impedes clinical diagnosis in early stages of the disease. At our patient’s presentation FA revealed only discrete multifocal peripheral lesions, which were clearly evident 11 months later. ICGA could have been an additional diagnostic tool displaying hypofluorescent lesions that were not visible clinically or on FA. The hypofluorescence is considered to represent non-perfusion areas of the choriocapillaris . Because of the myopic fundus with lacquer cracks it was difficult to diagnose CNV funduscopically. Late leakage in FA was discrete. Spaide et al. stated that in some cases differentiation between active inflammatory lesions and CNV may be impossible even with multimodal imaging as both can cause infiltrative lesions with breakdown of the blood-barrier . Our patient’s response to intravitreal bevacizumab confirmed the existence of CNV.
Treatment options for inflammation in MFC are oral, periocular, or intraocular steroids along with immunosuppressive agents . Our patient lacked systemic therapy for the first 11 months because further examinations were rejected. Therefore this case demonstrates that full outbreak of disease with multiple lesions of the central and peripheral fundus can develop without systemic treatment. Notably these lesions remained asymptomatic. On treatment with prednisolone administered orally and consecutive cyclosporine administered orally, her inflammation subsided illustrating the need of systemic immunosuppression. The number of lesions stagnated and a progressive pigmentation indicating cicatrization occurred.
Our case shows that CNV reactivation may occur despite effective immunosuppression, at least at the beginning of therapy. Nevertheless, immunosuppression is supposed to prevent CNV by reducing the inflammatory stimulus for neo-angiogenesis [5, 8]. Before starting and after cessation of systemic immunosuppression, CNV recurred at frequent intervals bilaterally. This emphasizes the importance of long-term effective immunosuppression and short-term control in MFC.
In our case secondary CNV responded to intravitreal bevacizumab. This is in accordance with studies where intravitreal anti-VEGF was beneficial for CNV secondary to MFC in terms of effectivity and safety [3, 5, 6, 9, 10]. A small number of re-injections – two at OD and three at OS over 3 years – were sufficient for CNV control. This is consistent with the literature . Other CNV treatment approaches such as argon laser photocoagulation, photodynamic therapy, and surgical excision are regarded to be inferior [1, 3, 4, 10]. In accordance with the literature, VA in our patient improved after intravitreal bevacizumab applications and no adverse events occurred .
In conclusion, MFC is a rare recurrent disease that predominantly affects young myopic women. Therefore a careful dilated fundus examination including the periphery is mandatory in all myopic women with CNV. As clinical diagnosis can be difficult, FA and ICGA are recommended for suspect cases. CNV occurrence seems to be associated with insufficient immunosuppression. When CNV is present it can be treated effectively with anti-VEGF therapy requiring only few re-injections.
Indocyanine green angiography
Optical coherence tomography
Vascular endothelial growth factor
Herbort CP, Papadia M, Piergiorgio N. Myopia and inflammation. J Ophthalmic Vis Res. 2011;6(4):270–83.
Fung AT, et al. Multifocal choroiditis without panuveitis: clinical characteristics and progression. Retina. 2014;34:98–107.
Fine H, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.
Parodi M, et al. Intravitreal bevacizumab for juxtafoveal choroidal neovascularisation secondary to multifocal choroiditis. Retina. 2013;33:953–6.
Winterhalter S, et al. Inflammatorische choroidale Neovaskularisationen. Klin Monatsbl Augenheilkunde. 2012;229:897–904.
Mansour A, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012;47(3):269–74.
Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33(7):1315–24.
Baxter SL, et al. Risk of Choroidal Neovascularization among the Uveitides. Am J Ophthalmol. 2013;156:468–77.
Troutbeck R, et al. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clin Exp Ophthalmol. 2012;40:60–72.
Parodi M, et al. Bevacizumab vs. photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.
No funding was received.
Availability of data and materials
KS analyzed and interpreted the patient data and was a major contributor in writing the manuscript. TM and HFR collected, analyzed, and interpreted the patient data. RG collected, analyzed, and interpreted the patient data and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
No ethics approval was needed in this case.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Schroeder, K., Meyer-ter-Vehn, T., Fassnacht-Riederle, H. et al. Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report. J Med Case Reports 10, 298 (2016). https://doi.org/10.1186/s13256-016-1069-2
- Multifocal choroiditis
- Chorioretinal lesions
- Secondary CNV
- Systemic immunosuppression
- Case report